30 April 2014
Invitation to Roche Analyst Event at ASCO 2014
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (30 May - 3 June 2014).
Marriott Downtown Chicago
Chicago A-D (Level 5)
540 North Michigan Avenue
Sunday, 1 June 2014
6:30pm to 8:00pm Central Daylight Time CDT (Chicago)
followed by a buffet reception.
Download to my calendar
- Cancer Immunotherapy: Translating science into medical benefit
Ira Mellman, Vice President, Cancer Immunology, Genentech
Hy Levitsky, Head Cancer Immunotherapy Experimental Medicine, Roche Pharma Research and Early Development
- Oncology pipeline update
Sandra Horning, Chief Medical Officer and Head Global Product Development
- Oncology business and strategy update
Daniel O'Day, Chief Operating Officer Roche Pharmaceutical
Date: 1 June 2014
- 6:00pm Registration desk opens
- 6:30pm Start of meeting
- 8:00pm End of meeting followed by a buffet reception
To register for the event, please follow the link (Password: Analyst2014)
Dial in to the conference 10-15 minutes prior to the scheduled start, using the following dial-in numbers (listen-only mode, no live-access to speakers):
+41 (0) 58 310 5000 (Europe and ROW) or
+44 (0) 203 059 5862 (UK) or
+1 (1) 631 570 5613 (USA)
To expedite the registration process on the day of the conference call, you may pre-register for the event. click here.
Alternatively a live audio webcast can be accessed via http://ir.roche.com.
The presentation slides will be available from the IR website at http://ir.roche.com following to the closure of the ASCO meeting.
A replay will be available as of 8:30am CEST/7:30am BST on 2 June for 48 hours. Access is by dialing:
+41 (0) 91 612 4330 (Europe and ROW) or
+44 (0) 207 108 6233 (UK) or
+1 (1) 631 982 4566 (USA)
Please enter the conference ID 18246 followed by the # sign
A replay of the webcast will be available on demand on the Roche website. click here.
Head of Investor Relations